Skip to main content

Advertisement

SpringerLink
Log in

Epicardial gene therapy and laser revascularization

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Despite the proven effectiveness of coronary bypass surgery and percutaneous angioplasty techniques, an increasing number of patients are presenting with severe, medically intractable angina who are not candidates for either procedure. Two alternative strategies, transmyocardial laser revascularization and exogeneous administration of angiogenic growth factors (therapeutic angiogenesis) are currently being evaluated in such patients. This review focuses on the current status of these two procedures, emphasizing their similarities and differences in order to provide insight into what role each may ultimately play in the management of patients with otherwise unrevascularizable myocardial ischemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Favaloro RG: Saphenous vein graft in the surgical treatment of coronary artery disease. J Thorac Cardiovasc Surg 1969, 58:178–185.

    PubMed  CAS  Google Scholar 

  2. Wearn JT, Mettler SR, Klumpp TG, et al.: The nature of the vascular communications between the coronary arteries and the chambers of the heart. Am Heart J 1933, 9:143–164.

    Article  Google Scholar 

  3. Sen PK, Udwadia TE, Kinare SG, et al.: Transmyocardial acupuncture, a new approach to myocardial revascularization. J Thorac Cardiovasc Surg 1965, 50:181–189.

    PubMed  CAS  Google Scholar 

  4. Mirosheini M, Clayton MM: Revascularization of the heart by laser. J Microsurg 1981, 2:253–260.

    Article  Google Scholar 

  5. March RJ: Transmyocardial Laser Revascularization with the CO 2 laser: One year results of a randomized, controlled trial. Seminars in Thoracic and Cardiovasc Surg 1999, 11:12–18.

    CAS  Google Scholar 

  6. Kantor B, McKenna CJ, Caccitolo JA, et al.: Transmyocardial and percutaneous myocardial revascularization: Current and future role in the treatment of coronary artery disease. Mayo Clinic Proc 1999, 74:585–592. This recently published review from the Mayo Clinic (Rochester, MN) group nicely summarizes the current state of the art of laser revascularization performed both transmyocardially and percutaneously. It summarizes the major clinical studies which have been performed in the last four to five years and focuses on the controversy related to mechanism of action.

    Article  CAS  Google Scholar 

  7. Hughes GC, Kypson AP, St.Louis JD, et al.: Improved perfusion and contractile reserve after transmyocardial laser revascularization in a model of hibernating myocardium. Ann Thor Surg 1999, 67 1714–1720.

    Article  CAS  Google Scholar 

  8. Horvath KA, Greene R, Belkind N, et al.: Left ventricular functional improvement after transmyocardial laser revascularization. Ann Thor Surg 1998, 66:721–725.

    Article  CAS  Google Scholar 

  9. Allen KB, Fudge TL, Schoettle P Jr, et al.: Prospective randomized multicenter trial of transmyocardial revascularization versus maximal medical management in patients with refractory class IV angina: 12-month results [abstract]. Circulation 1998, 98(Suppl I):I-476.

    Google Scholar 

  10. Jones WJ, Schmidt SE, Richman BW, et al.: Holmium: YAG laser transmyocardial revascularization relieves angina and improves functional status. Ann Thorac Surg 1999, 67:1596–1602. This recently published well-controlled prospective randomized study comparing TMR with medical treatment probably best summarizes the state of the art of TMR in the United States. Perioperative morbidity and mortality were very low and TMR recipients did significantly better than those treated medically at 1-year follow-up. The perioperative protocol is similar to that used in gene therapy studies allowing some degree of comparison.

    Article  PubMed  CAS  Google Scholar 

  11. Schofield PM, Sharples LD, Caine N, et al.: Transmyocardial laser revascularization in patients with refractory angina a randomized controlled trial. Lancet 1999, 353:519–524. This study caused considerable controversy in letters to the editor to Lancet following its publication. It essentially found that when treadmill exercise time was used as a major end point, TMR-treated patients did not improve significantly compared with the medica management group. Its findings tend to be at odds with most of the US studies and for that reason it needs to be critically reviewed and compared with them.

    Article  PubMed  CAS  Google Scholar 

  12. Moosdorf R: Transmyocardial laser revascularization [letter] Lancet 1999, 353 1705.

    Article  PubMed  CAS  Google Scholar 

  13. Lutter G, Saurbier B, Nitzsche E, et al.: Transmyocardial laser revascularization (TMLR) in patients with unstable angina and low ejection fraction. Eur J Cardiothorac Surg 1998, 13(1):21–26.

    Article  PubMed  CAS  Google Scholar 

  14. Nagele H, Stubbe HM, Nienaber C, et al.: Results of transmyocardial laser revascularization in non-revascularizable coronary artery disease after 3 years follow-up. Eur Heart J 1998, 19(10):1525–1530. This is the first publication in which a follow up of patients after TMR has been extended to 3 years. The 3-year follow-up data demonstrate somewhat of a fall off in angina class despite excellent early improvement. More importantly, the perioperative and late mortality focus on the increased risk associated with operating on patients with low ejection fractions and provide evidence that caution should be taken in regard to the wide spread use of this procedure as a treatment for patients with moderate anginal symptoms and poor left ventricular function.

    Article  PubMed  CAS  Google Scholar 

  15. Krabatsch T, Schaper F, Leder C, et al.: Histological findings after transmyocardial laser revascularization. J Card Surg 1996, 11-326–331.

    PubMed  CAS  Google Scholar 

  16. Sigel JE, Abramovich CM, Lytle BW, et al.: Transmyocardial laser revascularization: Three sequential autopsy cases. J Thor Cardiov Surg 1998, 115:1381–1384.

    Article  PubMed  CAS  Google Scholar 

  17. Fisher PE, Khomoto T, DeRosa CM, et al.: Histologic analysis of transmyocardial channels: Comparison of CO 2 and holmium:YAG lasers. Ann Thor Surg 1997, 64:466–742.

    Article  CAS  Google Scholar 

  18. Kohmoto T, Fisher PE, Gu A, et al.: Does blood flow through holmium:YAG transmyocardial laser channels? Ann Thor Surg 1996, 61:861–868.

    Article  CAS  Google Scholar 

  19. Malekan R, Reynolds C, Narula N, et al.: Angiogenesis in transmyocardial laser revascularization: A nonspecific response to injury. Circulation 1998, 98:II-62 66.

    Google Scholar 

  20. Hughes GC, Lowe JE, Kypson AP, et al.: Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Ann Thor Surg 1998, 66:2029–2036.

    Article  CAS  Google Scholar 

  21. Mueller XM, Tevaearai HT, Genton CY, et al.: Are there vascular density gradients along myocardial laser channels? Ann Thor Surg 1999, 68:125 130.

    Google Scholar 

  22. Yamamoto N, Kohmoto T, Gu A, et al.: Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization. J Am Coll Cardiol 1998, 31:1426–1433.

    Article  PubMed  CAS  Google Scholar 

  23. Kwong KF, Kanellopoulos GK, Nickols JC, et al.: Transmyocardial laser treatment denervates canine myocardium. J Thor Cardiov Surg 1997, 114:883–890.

    Article  PubMed  CAS  Google Scholar 

  24. Hughes GC, Landolfo KP, Lowe JE, et al.: Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization. Am Heart J 1999, 137 1163–1168. This study makes the important observation that ischemic events in the first 48 hours after TMR are common and usually clinically silent. In addition to recommending close follow-up and monitoring of TMR recipients early after surgery, it supports the concept that some degree of denervation may play a role in the mechanism of action of TMR and explain the immediate relief of symptoms often observed.

    Article  PubMed  CAS  Google Scholar 

  25. Al-Sheikh T, Allen KB, Straka SP, et al.: Cardiac sympathetic denervation after transmyocardial laser revascularization. Circulation 1999, 100:135–140. This interesting and sophisticated clinical study compares myocardial perfusion as documented by PET imaging with changes in sympathetic denervation measured by HED retention in the myocardium. Though the number of patients (eight) is small, studies again support the concept that sympathetic denervation may play an important part in the mechanism of action of TMR.

    PubMed  CAS  Google Scholar 

  26. Kwong KF, Schuessler RB, Kanellopoulos GK, et al.: Nontransmural laser treatment incompletely denervates canine mycardium. Circulation 1998, 98 II-67 72.

    Google Scholar 

  27. Chu V, Giaid A, Kuang J, et al.: Angiogenic response in transmyocardial revascularization: Comparison of laser vs. mechanical punctures. Ann Thor Surg 1999, 68:301–308.

    Article  CAS  Google Scholar 

  28. Chu V, Kuang J, McGinn A, et al.: Mechanical transmyocardial revascularization induced angiogenic response. J Thor Cardiov Surg. 1999, in press.

  29. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27–31.

    Article  PubMed  CAS  Google Scholar 

  30. Melillo G, Scoccianti M, Kovesdi I, et al.: Gene therapy for collateral vessel development. Cardiov Res 1997, 35:480–489.

    Article  CAS  Google Scholar 

  31. Lee LY, Rosengart TK: Transmyocardial laser revascularization and angiogenesis: The potential for therapeutic benefit. Seminars in Thor Cardiov Surg 1999, 11:29 35.

    Google Scholar 

  32. Rosengart TK, Patel S, Crystal RG: Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovas Risk 1999, 6:29–40. This excellent review article on angiogenesis is published in a relatively obscure journal but is worth seeking out. It is probably the most complete and up to date summary of the current status of angiogenesis research readily obtainable.

    CAS  Google Scholar 

  33. Connolly DT: Vascular permeability factor: A unique regulator of blood vessel function. J Cell Bioche 1991, 47 219–223.

    Article  CAS  Google Scholar 

  34. Asahara T, Bauters C, Zheng LP, et al.: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II–365-371.

    Google Scholar 

  35. Pepper MS, Ferrara N, Orci L, et al.: Potent synergism between vascular endothelial growth factor and fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992, 189:824 831.

    Article  PubMed  Google Scholar 

  36. Semenza GL: Transcriptional regulation by hypoxia-inducible factor l-molecular mechanisms of oxygen homeostasis. Trends Cardiovasc Med 1996, 6:151–157.

    Article  CAS  Google Scholar 

  37. Pu L, Lachapelle K, Graham A, et al.: Angiogenic stimulation: a new approach for severe chronic limb ischemia. Surg Forum 1991, XLII:365–367.

    Google Scholar 

  38. Harada K, Friedman M, Lopez JJ, et al.: Vascular endothelial growth factor in chronic myocardial ischemia. Am J Physiol 1996, 270:H1791-H1802.

    PubMed  CAS  Google Scholar 

  39. Hariawala M, Horowitz JR, Esakof D, et al.: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996, 63:77–82.

    Article  PubMed  CAS  Google Scholar 

  40. Selke F, Li J, Stamler A, et al.: Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 1996, 120:182–188.

    Article  Google Scholar 

  41. Tsurumi Y, Takeshita S, Chen D, et al.: Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissu perfusion. Circulation 1996, 98:I-526.

    Google Scholar 

  42. Tio RA, Lebherz C, Scheuermann TH Jr, et al.: Intramyocardial injection with naked DNA encoding for VEGF causes local and systemic production of VEGF, and improves collateral flow to ischemic myocardial tissue. Circulation 1998, 98:I-526.

    Google Scholar 

  43. Lee LY, Zhou X, Polce DR, et al.: Exogenous control of cardiac gene therapy: Evidence of regulated myocardial transgene expression after adenovirus and adeno-associated virus transfer of expression cassettes containing corticosteroid respons element promoters. J Thorac Cardiov Surg 1999, 118:26–35.

    Article  PubMed  CAS  Google Scholar 

  44. Laham RJ, Leimbach M, Chronos NA, et al.: Intracoronary administration of recombinant fibroblast growth factor-2 (rFGF-2) in patients with severe coronary artery disease: Results of Phase I. JACC 1999, 33:383A.

    Google Scholar 

  45. Henry TD, Annex BH, Azrin MA, et al.: Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial. JACC 1999, 33 384A.

    Google Scholar 

  46. Schumacher B, Pecher P, von Specht BU, et al.: Induction of neoangiogenesis in ischemic myocardium by human growth factors - First clinical results of a new treatment of coronary heart disease. Circulation 1998, 97:645–650. This article published last year is the first description in humans of angiographic evidence of development of new vessels following administration of an angiogenic growth factor. Although the authors did not compare the FGF-treated patients with controls in terms of clinical improvement the angiographic studies are nonetheless impressive and provide clinical support for the concept of therapeutic angiogenesis documented in animals models.

    PubMed  CAS  Google Scholar 

  47. Rosengart TK, Lee LY, Patel SR, et al.: Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100:468–474.

    PubMed  CAS  Google Scholar 

  48. Symes JF, Losordo DW, Vale PR, et al.: Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thor Surg. 1999, in press. This study documents the results of a Phase I trial in which plasmid DNA encoding for VEGF165 was administered to otherwise-inoperable patients with medically intractable angina as the only therapeutic intervention. As such it provides the first clinical evidence that angiogenic gene therapy is safe and can significantly improve angina in the majority of patients. The relief of angina is also correlated with improvements in myocardial perfusion by sestamibi scans.

  49. Kornowski R, Bhargava B, Leon M: Percutaneous transmyocardial laser revascularization: An overview. Cathet Cardiovasc Intervent 1999, 47:354–359. This recently published review article summarizes the current state of the art with regard to percutaneous TMR. It describes the various commercially available systems and the studies which have been conducted with them.

    Article  CAS  Google Scholar 

  50. Vale PR, Losordo DW, Tkebuchava T, et al.: Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. JACC 1999, 34:246–254.

    PubMed  CAS  Google Scholar 

  51. Sayeed-Shah U, Mann MJ, Martin J, et al.: Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. J Thorac Cardiovasc Surg 1998, 116:763–769.

    Article  PubMed  CAS  Google Scholar 

  52. Yamamoto N, Kohmoto T, Gu A, et al.: Basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization. Circulation 1998, 98:I-217.

    Google Scholar 

  53. Hughes C, Annex B, Yin B, et al.: Transmyocardial laser revascularization (TMR) limits in vivo adenoviral-mediated gen transfer in porcine myocardium JACC 1999, 33:355A.

    Google Scholar 

  54. Allen KB, Delrossi AJ, Lefrak EA, et al.: Transmyocardial revascularization combined with coronary artery bypass grafting versus coronary artery bypass grafting alone: Results of a prospective randomized, multi-center trial. Circulation 1998, 98:I-217.

    Google Scholar 

  55. Trehan N, Mishra Y, Mehta Y, et al.: Transmyocardial laser as an adjunct to minimally invasive CABG for complete myocardial revascularization. Ann Thor Surg 1998, 66:1113–1118.

    Article  CAS  Google Scholar 

  56. Sellke FW, Laham RJ, Edelman ER, et al.: Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results. Ann Thor Surg. 1998, 1540–1544.

  57. Burkhoff D, Wesley MN, Resar JR, et al.: Factors correlating with risk of mortality after transmyocardial revascularization. J Am Coll Cardiol 1999, 34:55–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Elizabeth's Medical Center, 11 Nevins Street, 02135, Boston, MA, USA

    James F. Symes MD

Authors
  1. James F. Symes MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Symes, J.F. Epicardial gene therapy and laser revascularization. Curr Cardiol Rep 1, 335–343 (1999). https://doi.org/10.1007/s11886-999-0060-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-999-0060-6

Keywords

Search

Navigation